aDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health
bWelch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland
cDepartment of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, Alabama
dKidney Health Research Institute, Geisinger Health, Danville, Pennsylvania, USA
Correspondence to Kathryn Foti, PhD, MPH, 2024 E. Monument Street, Suite 2-600, Baltimore, MD 21287, USA. Tel: +1 410 955 4156; fax: +1 410 955 0476; e-mail: [email protected]
Received 27 July, 2021
Revised 15 November, 2021
Accepted 2 December, 2021
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).
Abbreviations: ACC, American College of Cardiology; AHA, American Heart Association; ALLHAT, Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial; BP, blood pressure; CI, confidence interval; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; NHANES, National Health and Nutrition Examination Survey; PR, prevalence ratio; SE, standard error; SPRINT, Systolic Blood Pressure Reduction Intervention Trial; USPSTF, US Preventive Services Task Force
